(Reuters) - After three decades without bringing a drug to market, Sarepta Therapeutics Inc stands on the verge of a breakthrough with its treatment for a crippling genetic disorder that affects one in every 3,500 newborn boys.https://mf.feeds.reuters.com/c/871/f/...a4271bc/mf.gif
https://da.feedsportal.com/r/16199089...a4271bc/a2.imghttps://pi.feedsportal.com/r/16199089...4271bc/a2t.img
More...
